BACKGROUND Left atrial appendage closure (LAAC) and nonwarfarin oral anticoagulants (NOACs) have emerged as safe and effective alternatives to warfarin for stroke prophylaxis in patients with nonvalvular atrial fibrillation (AF). OBJECTIVES This analysis assessed the cost-effectiveness of warfarin, NOACs, and LAAC with the Watchman device (Boston Scientific, Marlborough, Massachusetts) for st...

Objective: To evaluate the cost-effectiveness of monthly and as-needed dosing protocols using ranibizumab or bevacizumab for the treatment of neovascular age-related macular degeneration (AMD), when the treatment costs of severe ocular and systemic adverse events are considered. Methods: A Markov model was developed to assess the cost effectiveness of each of the following protocols: monthly ra...

During these last years, there have been an increased number of new drugs for non-small cell lung cancer (NSCLC), with a growing financial effect on patients and society. The purpose of this article was to review the economics of first-line and maintenance NSCLC treatments. We reviewed economic analyses of NSCLC therapies published between 2004 and 2014. In first-line settings, in unselected pa...

The value for money associated with pembrolizumab versus nivolumab has not been evaluated head-to-head. objective of this analysis is to assess the cost-effectiveness in advanced or metastatic NSCLC patients from a third-party payer’s perspective. We developed three-state transition model [progression-free survival(PFS), post-progression survival, and death] based on phase III KEYNOTE-042 trial...

Cost-effectiveness analysis made its first appearance in the health care literature more than 4 decades ago. In Britain, the National Institute of Clinical Excellence (NICE) explicitly considers cost per quality-adjusted life year (QALY) gained among its criteria for coverage recommendations to the National Health Service; some observers have inferred that explicit criteria such as £30,000 per ...

ObjectivesIn Germany, routine influenza vaccination with quadrivalent vaccines (QIV) is recommended and reimbursed for individuals ?60 years of age underlying chronic conditions. The present study examines the cost-effectiveness a possible extension recommendation to include strategies childhood against seasonal using QIV.MethodsA dynamic transmission model was used examine epidemiological impa...

Mavacamten is a first-in-class cardiac myosin modulator for HOCM, which genetic disorder of the sarcomere. This study assessed cost effectiveness mavacamten in addition to standard care (SoC) compared with SoC alone, as well disopyramide, myectomy, and septal ablation each SoC. A semi-Markov model was used over lifetime time horizon from healthcare sector perspective cycle length 4 weeks. Patie...

Background The measurement of health benefits is a key issue in health economic evaluations. There is very scarce empirical literature exploring the differences of using quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs) as benefit metrics and their potential impact in decision-making.   Methods Two previously published models delivering outputs in QALYs, were adapted...

The AMBUVASC trial evaluated the cost effectiveness of outpatient vs. inpatient hospitalisation for endovascular repair lower extremity arterial disease (LEAD). was a national multicentre, prospective, randomised controlled conducted in nine public and two private French centres. primary endpoint incremental ratio (ICER), defined by per quality adjusted life year (QALY). Analysis from societal ...